KR840007873A - N-[w-(1h-이미다졸-1-일)알킬] 아릴아미드 및 n-[w-(1h-이미다졸-1-일)알킬) 프탈아미드의 제조방법. - Google Patents

N-[w-(1h-이미다졸-1-일)알킬] 아릴아미드 및 n-[w-(1h-이미다졸-1-일)알킬) 프탈아미드의 제조방법. Download PDF

Info

Publication number
KR840007873A
KR840007873A KR1019840000951A KR840000951A KR840007873A KR 840007873 A KR840007873 A KR 840007873A KR 1019840000951 A KR1019840000951 A KR 1019840000951A KR 840000951 A KR840000951 A KR 840000951A KR 840007873 A KR840007873 A KR 840007873A
Authority
KR
South Korea
Prior art keywords
alkyl
formula
hydrogen
imidazol
inert solvent
Prior art date
Application number
KR1019840000951A
Other languages
English (en)
Inventor
부라이스 라이트 쥬니어(외1) 윌리암
Original Assignee
죤 제이 헤이간
아메리칸 사이아나밋드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 죤 제이 헤이간, 아메리칸 사이아나밋드 캄파니 filed Critical 죤 제이 헤이간
Publication of KR840007873A publication Critical patent/KR840007873A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

내용 없음.

Description

N-[W-(1H-이미다졸-1-일)알킬] 아릴아미드 및 N-[W-(1H-아미다졸-1-일)알킬) 프탈아미드의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 하기 구조식(Ⅰ)의 산을 주위 온도에서와 불활성 용매중에서 1,1′-카르보닐이미다졸과 축합하여 하기 구조식(2)의 중간체를 생성한 다음, 이 중간체를 하기 구조식(3)의 디아민을 환류온도에서와 불활성 용매중에서 반응하는 것을 특징으로 하는 하기 구조식(4)를 갖는 N-[W-(1H-이미다졸-1-일)알킬]아릴아미드의 제조방법.
    상기식에서, A는 CnH2n-, (여기서 n은 2-8의 정수임)또는의 2가기이고, ARYL은 1-나프틸, 2-나프틸, 디페닐메틸, 9-플루오레닐 또는
    (여기서, R1, R2및 R3는 각각 수소, 할로겐, 트리풀루오로메틸, 시아노, 카르복시, 아미노, 알킬(C1-C4) 알콕시 벤질아미노, 알릴아미노, 알킬(C1-C|4)아미노, 디알킬 아미노, 알킬(C1-C3)티오, 알킬(C1-C3)설포닐, 아세틸, 아세틸아미노, 페닐 또는 벤조일임) ;
    Q는(여기서, 은 0,1,2 또는 3)임
    의 또는 의 2가기이고, R4는 수소, 알킬(C1-C3) 또는 벤질이고, R5및 R6는 각각 수소, 알킬(C1-C3) 또는 페닐이다.
  2. 하기 구조식(5)의 화합물을 산수용체의 존재하에 주위 온도와 불활성 용매중에서 하기 구조식(3)의 디아민과 축합하는 것을 특징으로 하는 하기 구조식(4)를 갖는 N-[W-(1H-이미다졸-1-일)알킬]아릴아미드의 제조방법.
    상기식에서 A, ARYL, R4, R5, R6및 Q는 상기에서 규정한 바와 같고, X는 클로로, 브로모 또는 -O-CO-Q-ARYL 구조를 갖는 기이다.
  3. 하기 구조식(14)의 치환된 프탈이미드를 30°내지 100℃의 불활성 용매중에서 하기 구조식(15)의 치환된 N-할로알킬 이미다졸과 축합하는 것을 특징으로 하는 하기 구조식(16)을 갖는 N-[W-(1H-이미다졸-1-일)알킬] 프탈이미드의 제조방법.
    상기식에서 P는 3-10의 정수이고 ; R5및 R6는 각각 수소, 알킬(C1-C3) 또는 페닐이고 ; R9및 R10은 각각 수소, 할로겐, 알킬(C1-C3), 니트로 또는 아미노이고(단, P가 3일 때 R9와 R10는 모두 수소가 아님) X는 클로로, 브로모 또는 요오드이다.
  4. 하기 구조식(14)의 치환된 프탈이미드 또는 하기 구조식(19)의 무수 프탈산을140°내지 190℃의 고비점 불활성 용매중에서 하기 구조식(20)의 N-아미노알킬 이미다졸과 축합하는 것을 특징으로 하는 하기 구조식(16)을 갖는 치환된 이미다졸-1-일) 알킬 프탈이미드의 제조방법.
    상기식에서 P, R5,R6,R9및 R10은 제3항에서 규정한 바와 같다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019840000951A 1983-02-28 1984-02-27 N-[w-(1h-이미다졸-1-일)알킬] 아릴아미드 및 n-[w-(1h-이미다졸-1-일)알킬) 프탈아미드의 제조방법. KR840007873A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47011283A 1983-02-28 1983-02-28
US470112 1983-02-28

Publications (1)

Publication Number Publication Date
KR840007873A true KR840007873A (ko) 1984-12-11

Family

ID=23866324

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840000951A KR840007873A (ko) 1983-02-28 1984-02-27 N-[w-(1h-이미다졸-1-일)알킬] 아릴아미드 및 n-[w-(1h-이미다졸-1-일)알킬) 프탈아미드의 제조방법.

Country Status (9)

Country Link
EP (1) EP0117462A3 (ko)
JP (1) JPS59164779A (ko)
KR (1) KR840007873A (ko)
AU (1) AU2507284A (ko)
DD (1) DD218890A5 (ko)
DE (1) DE3406416A1 (ko)
DK (1) DK77884A (ko)
GR (1) GR81797B (ko)
ZA (1) ZA841447B (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH655103A5 (de) * 1983-03-11 1986-03-27 Sandoz Ag Azolderivate, verfahren zu ihrer herstellung und ihre verwendung.
US4916145A (en) * 1987-07-10 1990-04-10 Hoffmann-La Roche Inc. Substituted n-[(pyridyl)alkyl]aryl-carboxamide
US5100909A (en) * 1988-07-25 1992-03-31 The Upjohn Company Acetylenic imidazoles having central nervous system activity
EP0426714B1 (en) * 1988-07-25 1996-04-03 The Upjohn Company Acetylenic imidazoles having central nervous system activity
US4962120A (en) * 1989-03-22 1990-10-09 Sterling Drug Inc. 1H-imidazole-1-acetamides
GB9127304D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
GB9312893D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
WO1995022327A1 (en) * 1994-02-22 1995-08-24 Knoll Ag Use of 1-(arylalkylaminoalkyl) imidazoles for treating neurological damage
DE19729640A1 (de) * 1996-08-17 1998-02-19 Ciba Geigy Ag Verfahren zur Herstellung von Nitrobenzamiden oder Aminobenzamiden
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
SE0002531D0 (sv) * 2000-07-05 2000-07-05 Active Biotech Ab Immune Enhancement
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
JP4996926B2 (ja) * 2004-02-05 2012-08-08 プロビオドルグ エージー グルタミニルシクラーゼの新規の阻害剤
US9012494B2 (en) 2004-05-07 2015-04-21 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
RU2386617C2 (ru) 2004-08-30 2010-04-20 Янссен Фармацевтика Н.В. ПРОИЗВОДНЫЕ ТРИЦИКЛИЧЕСКОГО ЛАКТАМА В КАЧЕСТВЕ ИНГИБИТОРОВ 11-β-ГИДРОКСИСТЕРОИДНОЙ ДЕГИДРОГЕНАЗЫ
NZ553159A (en) 2004-08-30 2010-05-28 Janssen Pharmaceutica Nv N-Adamantan-2-yl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
CA2635335A1 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
MX2015007862A (es) * 2012-12-28 2016-02-05 Nippon Zoki Pharmaceutical Co Derivado de amida del acido cinamico.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646057A (en) * 1969-04-06 1972-02-29 Hoffmann La Roche 2-nitroimidazoles
DE2854598A1 (de) * 1978-12-18 1980-07-03 Basf Ag N-substituierte carbonsaeureanilide, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide

Also Published As

Publication number Publication date
DE3406416A1 (de) 1984-08-30
AU2507284A (en) 1984-09-06
EP0117462A3 (en) 1986-08-20
EP0117462A2 (en) 1984-09-05
DK77884A (da) 1984-08-29
DD218890A5 (de) 1985-02-20
ZA841447B (en) 1984-10-31
JPS59164779A (ja) 1984-09-17
DK77884D0 (da) 1984-02-20
GR81797B (ko) 1984-12-12

Similar Documents

Publication Publication Date Title
KR840007873A (ko) N-[w-(1h-이미다졸-1-일)알킬] 아릴아미드 및 n-[w-(1h-이미다졸-1-일)알킬) 프탈아미드의 제조방법.
KR870000289A (ko) 트리시클로데칸의 (메트)-아크릴산 유도체의 제조방법
KR880011151A (ko) 티아제핀 화합물의 제조방법
KR840000592A (ko) 이소이미드를 함유하는 소중합체류의 제조방법
KR840003602A (ko) 인다닐벤즈아미드 유도체의 제조방법
KR910014351A (ko) 치환된 2-클로로피리딘의 제조방법
US4499285A (en) Solvent free preparation of diarylthioethers
US4625037A (en) Method for making thioether(bisphthalimide)s
US5393854A (en) Colorless, purified polymerizable composition useful for the production of crosslinked polyvinylpyrrolidone
JPS63215662A (ja) ビス（ｎ置換フタルイミド）エーテルの合成法
CA1168235A (fr) Procede de n-alkylation de composes organiques azotes
KR880001615A (ko) 5,6-치환-2,4-퀴나졸인디아민 및 신규의 중간 생성물을 제조하는 향상된 방법
US4479006A (en) Process for the preparation of 1-carbamoyl-3-(3,5-dichlorophenyl)-hydantoins
KR920004397A (ko) 1-옥사-3,8-디아자-4-옥소스피로[4,5]데칸 화합물의 제조방법.
KR850005838A (ko) 1,3,2-디옥사보리난의 제조방법
RU98112016A (ru) Способ получения диоксоазабициклогексанов
KR930009994A (ko) 3-펜옥시-1-아제티딘카복스아미드를 합성하는 우레아융합법
KR890700587A (ko) 항궤양 작용의 화합물 제조방법
KR860004024A (ko) 인돌 제조방법
KR840005086A (ko) N-치환된-3.4.5.6-테트라하이드로프탈람 산유도체의 제조방법
KR960034165A (ko) 방향족 니트릴의 제조 방법
ES8407042A1 (es) Procedimiento para la obtencion de un nuevo derivado del sulpiride.
CS214537B1 (cs) Způsob výroby 4-amino-4H-1,2,4-triazolu
KR920002559A (ko) N-알킬설포닐아미노설포닐우레아의 제조방법
KR960041157A (ko) 2-플루오로시클로프로필아민 술폰산염의 제조 방법 및 2-플루오로시클로-프로필이소시아네이트 화합물

Legal Events

Date Code Title Description
WITB Written withdrawal of application